Leaderboards/Urinary and Genital Oncology Studies

Urinary and Genital Oncology Studies

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Chen Ding
Xinjiang Medical University
66
2
Mikio Sugimoto
Kagawa University
57
3
Yongqiang Wang
Anhui Medical University
48

Rising Stars Papers

1
Proteogenomic characterization of skull-base chordoma
Nature Communications|2024
13 cit.
2
Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy
BMC Immunology|2025
2 cit.
3
Comprehensive proteomic characterization of urethral stricture disease in the Chinese population
Frontiers in Molecular Biosciences|2024
1 cit.
4
Combined Inhibition of PI3K and STAT3 Signaling is Effective in Bladder Cancer Treatment
Research Square|2024
0 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Kun-Lin Hsieh
Chi Mei Medical Center
99
2
Konstantinos Kossenas
University of Nicosia
99
3
Yin Wang
University of Michigan
90
4
Abolfazl Razzaghdoust
Shahid Beheshti University of Medical Sciences
62
5
Gang Li
Kagoshima University
50
6
Hirohito Naito
Kagawa University
38
7
Tianxiang Zhang
Shanghai Jiao Tong University
32

Emerging Leaders Papers

1
Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer
BMC Medical Imaging|2025
5 cit.
2
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion
Oncogene|2025
2 cit.
3
Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy
BMC Immunology|2025
2 cit.
4
CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells
PLoS ONE|2025
1 cit.
5
Intracorporeal Versus Extracorporeal Urinary Diversion Following Robotic-Assisted Radical Cystectomy for Bladder Cancer in Patients ≥ 65 Years of Age: A Systematic Review and Meta-Analysis
Cureus|2025
0 cit.
6
Molecular and immune characteristics of neuroendocrine bladder carcinoma — Implications for diagnosis, prognosis, and therapy: A review
Biomolecules and Biomedicine|2025
0 cit.
7
Therapeutic strategies for <scp>MMAE</scp> ‐resistant bladder cancer through <scp>DPP4</scp> inhibition
Molecular Oncology|2025
0 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Dan Theodorescu
Cedars-Sinai Medical Center
91
2
Luc Friboulet
Inserm
87
3
Hiroshi Miyamoto
University of Rochester Medical Center
84
4
Julie Brown
University of Auckland
76
5
Dong‐Myung Shin
Ulsan College
72
6
Peter C. Black
University of British Columbia
66
7
In‐Sun Chu
Yonsei University
65
8
Maurice P. Zeegers
Maastricht University Medical Centre
63
9
Guoli Chen
Geisinger Medical Center
61
10
Patrick H. Viollier
University of Geneva
60

All-Time Leaders Papers

1
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Cancer Discovery|2014
842 cit.
2
Advances in bladder cancer biology and therapy
Nature reviews. Cancer|2020
783 cit.
3
Expression Signature of <i>E2F1</i> and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors
Journal of Clinical Oncology|2010
352 cit.
4
Lifestyle interventions for the treatment of women with gestational diabetes
Cochrane Database of Systematic Reviews|2017
282 cit.
5
Surgery for women with anterior compartment prolapse
Cochrane Database of Systematic Reviews|2016
267 cit.
6
Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses
European Journal of Epidemiology|2016
229 cit.
7
Chromium Activates Glucose Transporter 4 Trafficking and Enhances Insulin-Stimulated Glucose Transport in 3T3-L1 Adipocytes via a Cholesterol-Dependent Mechanism
Molecular Endocrinology|2005
184 cit.
8
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer
Nature Communications|2021
174 cit.
9
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Clinical Cancer Research|2018
125 cit.
10
Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
Endocrine Related Cancer|2011
103 cit.

Reagents for Urinary and Genital Oncology Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

Tri-Methyl-Ezh2 (Lys509) (F1D1Q) Rabbit Monoclonal Antibody

#9994$176
View Evidence →Cell Signaling Technology

TGF-beta Receptor III (D11G10) Rabbit Monoclonal Antibody

#5544$161
View Evidence →Agilent/Dako

CD20cy

#M0755
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

#75864$493
View Evidence →Cell Signaling Technology

SH3BP4 (D3D9I) Rabbit Monoclonal Antibody

#55935$161
View Evidence →Agilent/Dako

Collagen IV

#M0785
View Evidence →